The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review

The global prevalence of human immunodeficiency virus (HIV) has led to a significant rise in the chronic use of antiretroviral (ARV) drugs, both for HIV management and pre-exposure prophylaxis (PrEP), to meet the set Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets. Although anti...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Amogelang Sedibe, Ntethelelo Sibiya, Trevor Nyakudya, Mlindeli Gamede
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-12-01
Sarja:	Biochemistry and Biophysics Reports
Aiheet:	HIV- antiretroviral therapy HIV-Fixed-dose combination therapy Prediabetes Type 2 diabetes mellitus Drug-metabolic complications Pancreatic health outcomes
Linkit:	http://www.sciencedirect.com/science/article/pii/S2405580825004327
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!